

Mayssa Attar

Associate Vice President - Clinical Pharmacology, Metabolism and Immunology at Allergan

Summary

18+ years drug development experience in clinical pharmacology, pharmacokinetics, pharmacodynamics and drug metabolism. Diplomate of the American Board of Toxicology.

Key roles in which I serve(d) include:

- Clinical Pharmacology Head
- Pharmacokinetics and Pharmacodynamics Head
- Global Project Team Leader delivering a Phase 3 asset with >\$1 billion/year commercial opportunity
- Oversight of a >\$80 million annual budget for a Phase 3 program
- Adjunct Assistant Professor at the University of Southern California, School of Pharmacy.

Major accomplishments include: 7 successive promotions with increasing scope of responsibility over 15 years, positioned PK/PD data to support regulatory strategy and gained additional patent protection for >billion dollar in sales product, negotiated and partnered with Emerging Market country's Ministry of Health to present PK and safety data to reverse a government directive to support first marketing approvals, consistent performance in identifying and developing talent for the organization.

Developed small and large molecule drugs and devices across multiple therapeutic areas including ophthalmology (inflammation, dry eye, glaucoma and retinal disease), CNS (neuropathic pain, migraine and movement disorders), urology, dermatology (acne, rosacea, hair growth) and medical aesthetics.

Successfully serve as a liaison representing clinical pharmacology and nonclinical development to global health authorities/site inspectors, USPTO and KOLs to support business critical projects. Act as an expert witness to support litigation associated with intellectual property. Represent R&D during in-licensing and technology assessments in collaboration with legal and commercial colleagues. Participated in integration teams for mergers and acquisitions with experience representing the acquiring company and the acquired company.

Experience

Associate Vice President - Clinical Pharmacology, Metabolism and Immunology at Allergan

January 1999 - Present

Allergan Inc was acquired by Actavis plc in Mar 2015 and the new company adopted the name Allergan plc. In the new company, my scope of responsibility increased to include oversight of the ADME group and Immunology group in addition to my responsibility for oversight of the Clinical Pharmacology/PKPD group. I currently report to the R&D site head.

MYLAN - EXHIBIT 1033

Lead a team of scientists responsible for the integrated assessment of nonclinical through clinical Pharmacokinetics and Pharmacodynamics supporting Allergan's entire R&D portfolio. Member of the Nonclinical Development Leadership team that provides departmental strategic and operational oversight. Team member in organizational restructuring/change management efforts to improve departmental efficiencies.

Final accountability for successful support of Allergan's entire R&D portfolio through the strategic and technical oversight of clinical and nonclinical pharmacokinetic, drug metabolism, PK/PD modeling and simulation activities.

Provide direction for identifying and developing talent to build technical capabilities (in silico, in vitro, in vivo and clinical PK/pharmacology) and strengthen project representation. Cross-functional team leader for early development through market launch teams.

Serve as a lead representative when interacting with global regulatory agencies, health authority site inspectors, USPTO, KOLs, due diligence interactions, legal and commercial colleagues/activities.

One of the original founders and team member for Allergan's first "Accelerator/Incubator" drug development team.

Received 7 successive promotions with increasing scope of responsibility over the past sixteen years. Associate Professional/Professional/Senior Professional/Scientist/Senior Scientist/Principal Scientist/Director/Senior Director.

Adjunct Assistant Professor at University of Southern California

December 2010 - Present

Develop course materials, learning aids, exams and offer lectures on the subjects of Pharmacokinetics, Pharmacodynamics, Drug Metabolism and Pharmacogenomics.

Mentor students as they consider careers in industry including acting as a mentor to PharmD and PhD fellows.

Online Instructor at American College of Clinical Pharmacology

2007 - 2014 (7 years 11 months)

Served as an instructor for FDA/ACCP online course "Future of Medicine: Pharmacogenomics" Module 4, Drug Metabolism. Support for the course was provided by GlaxoSmithKline and Third Wave Technologies. Introductory Modules given by Gilbert J. Burckart and Lawrence Lesko of FDA. <http://news.usc.edu/17201/USC-School-of-Pharmacy-professor-helps-create-online-drug-monitoring-course/>

Research Associate at Ottawa Hospital Research Institute

1995 - 1998 (3 years 11 months)

Summer Intern at The Ottawa Hospital

May 1994 - September 1994 (4 months)

Cardiology Unit

Education

University of Southern California

Doctor of Philosophy (Ph.D.), Pharmaceutical Sciences

Activities and Societies: Rho Chi Society

University of Ottawa

Master's Degree, Biochemistry

University of Ottawa

Bachelor's Degree, Biochemistry

Mayssa Attar

Associate Vice President - Clinical Pharmacology, Metabolism and Immunology at Allergan



[Contact Mayssa on LinkedIn](#)